|
|
|
March 20, 2012 | Even though Europe's financial system has been on charging downhill recently, several venture firms have invested heavily in European biotech in recent months. Their argument: the science and the talent exist, and experienced executives are looking for entrepenurial opportunities. But does that really outweigh the negatives? Xconomy
|
|
|